- Home
- INTA vs DNLI Comparison
INTA vs DNLI Comparison
Compare INTA & DNLI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INTA
- DNLI
- Stock Information
- Founded
- INTA 2000
- DNLI 2013
- Country
- INTA United States
- DNLI United States
- Employees
- INTA N/A
- DNLI N/A
- Industry
- INTA Computer Software: Prepackaged Software
- DNLI Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- INTA Technology
- DNLI Health Care
- Exchange
- INTA Nasdaq
- DNLI Nasdaq
- Market Cap
- INTA 3.8B
- DNLI 4.5B
- IPO Year
- INTA 2021
- DNLI 2017
- Fundamental
- Price
- INTA $56.13
- DNLI $25.05
- Analyst Decision
- INTA Strong Buy
- DNLI Strong Buy
- Analyst Count
- INTA 12
- DNLI 11
- Target Price
- INTA $53.82
- DNLI $38.90
- AVG Volume (30 Days)
- INTA 675.9K
- DNLI 788.0K
- Earning Date
- INTA 11-04-2024
- DNLI 11-06-2024
- Dividend Yield
- INTA N/A
- DNLI N/A
- EPS Growth
- INTA N/A
- DNLI N/A
- EPS
- INTA N/A
- DNLI N/A
- Revenue
- INTA $447,753,000.00
- DNLI N/A
- Revenue This Year
- INTA $17.72
- DNLI N/A
- Revenue Next Year
- INTA $14.96
- DNLI $283.75
- P/E Ratio
- INTA N/A
- DNLI N/A
- Revenue Growth
- INTA 20.07
- DNLI 204.74
- 52 Week Low
- INTA $30.36
- DNLI $14.56
- 52 Week High
- INTA $60.89
- DNLI $33.33
- Technical
- Relative Strength Index (RSI)
- INTA 61.25
- DNLI 37.93
- Support Level
- INTA $48.58
- DNLI $26.17
- Resistance Level
- INTA $60.89
- DNLI $33.33
- Average True Range (ATR)
- INTA 2.32
- DNLI 1.64
- MACD
- INTA 0.23
- DNLI -0.13
- Stochastic Oscillator
- INTA 61.36
- DNLI 0.66
About INTA Intapp Inc.
Intapp Inc is a provider of industry-specific, cloud-based software solutions for the professional and financial services industry. It empowers private capital, investment banking, legal, accounting, and consulting firms with the technology needed to meet rapidly changing client, investor, and regulatory requirements. Geographically, it derives a majority of its revenue from the United States and also has a presence in the United Kingdom and the Rest of the world.
About DNLI Denali Therapeutics Inc.
Denali Therapeutics Inc is a biotechnology company that is engaged in developing and discovering therapeutics to defeat neurodegeneration disease. The company's development programs include the LRRK2 Inhibitor Program, which develops brain penetrant small molecule LRRK2 inhibitor product candidates for Parkinson's disease. Its key products include DNL201, DNL151, DNL747, ATV (Antibody Transport Vehicle), ETV (Enzyme Transport Vehicle), and others.